You are here

Report: COPD Costs $36 Billion Per Year in U.S.

Annual direct medical costs projected to increase to $49 billion by 2020

The American College of Chest Physicians has announced the publication of a report on the total and state-specific medical and absenteeism costs of chronic obstructive pulmonary disease (COPD) among adults in the U.S. for 2010 and projections through 2020.

The report, presented by researchers at the Centers for Disease Control and Prevention (CDC), finds that, in 2010, the total national medical costs attributable to COPD were estimated at $32.1 billion annually. In addition, absenteeism costs were $3.9 billion, for a total burden of $36 billion in COPD-attributable costs.

Further, an estimated 16.4 million days of work were lost due to COPD each year. Of the medical cost, 18% was paid for by private insurance, 51% by Medicare, and 25% by Medicaid.

The study also projects an increase in medical costs from $32.1 billion in 2010 to $49 billion by 2020.

Chronic lower respiratory diseases, including COPD, are the third-leading cause of death in the U.S. COPD claimed the lives of 134,676 people in 2010. In 2011, 12.7 million U.S. adults were estimated to have COPD. However, close to 24 million U.S. adults have evidence of impaired lung function, indicating an under-diagnosis of COPD. Smoking is a primary risk factor for COPD, and approximately 80% of COPD deaths can be attributed to smoking.

“Evidence-based interventions that prevent and reduce tobacco use and reduce clinical complications of COPD may result in potential decreased COPD-attributable costs,” said Earl Ford, MD, MPH, of the CDC’s Division of Population Health.

The report also offers state-by-state data. “For the first time, our analyses provide state-specific costs for COPD, which provide state public health practitioners with estimates of the economic burden of COPD within their borders and illustrates the potential medical and absenteeism costs savings to states through implementing state level programs that are designed to prevent the onset of COPD,” Ford said.

Source: Chest; July 24, 2014.

Recent Headlines

Nitrosamine Impurity Also Affects Other Ranitidine Drugs
Mesh Implants, Now Banned by FDA, Work as Well as Hysterectomy
One in Five Kids’ Office Visits Results in an Off-Label Rx
Related Settlement Would End Many but Not All Lawsuits
Chronic Kidney Patients With Hyperphosphatemia May Be Another Market for the Drug
Disrupting Gut Microbiome Could Be Key
Drug Boosts Levels of Natural Endocannabinoids
Judicious Use of Antibiotics May Not Be Enough To Defeat Bacteria That Carry On By Going Into a Dormant State
KRAS Oncogene Is a Problematic Target So Researchers Are Trying Workdarounds